Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4th Generation CAR T Cells in Relapsed or Late-Stage Sarcoma
NCT03356782Phase 2Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2027
- Primary completion
- Dec 2029
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Sarcoma-specific CAR-T cells in sarcoma, osteosarcoma (OS), Ewing sarcoma, sponsored by Shenzhen Geno-Immune Medical Institute. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
Sarcoma-specific CAR-T cells
03
Conditions
sarcomaosteosarcoma (OS)Ewing sarcoma
Beyond the preview
Go deeper on NCT03356782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03356782.